spacer
home > ict > autumn 2009 > different countries, different approaches
PUBLICATIONS
International Clinical Trials

Different Countries, Different Approaches

 

Since the establishment of ICH-GCP, the globalisation of clinical trials has proven to be an irreversible trend. Pharmaceutical and biotechnology companies (mainly through CROs) are increasingly testing their candidate drugs in Latin America, eastern Europe and in the Asia-Pacific region. Each of these regions is composed of many different countries, each with their own clinical research regulations.

From an operational standpoint, it is not very difficult to reconcile the differences of clinical practices around the globe, although there are particularities. The operational implementation of a clinical protocol is basically the same from one place to another, and it is possible to conduct a global multi-centric study while maintaining the quality of the generated data.

From a legal standpoint, this same globalisation scenario can be slightly different. Legal systems may have a number of similarities, but unlike the ethical and operational aspects, legal differences are harder to standardise and globalise.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vitor Harada is a Clinical Development professional with 11 years of experience. He graduated in Pharmacy and Biochemistry from the University of São Paulo (USP) and has a MBA from the Fundação Getulio Vargas (FGV). Vitor is currently a Director of Clinical Operations at ICON and responsible for the company’s office in Brazil. He is also President of ABRACRO (Brazilian Association of CROs) and one of the Professors/Coordinators of the Clinical Research Postgraduation Course of the Santa Casa de São Paulo Medical School. In the past, Vitor has worked for AstraZeneca (where he was the local Head of the Clinical Department), Pharmacia and Bristol-Myers Squibb.
spacer
Vitor Harada
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT’s At-Home Cardiac Safety Assessment Ensures Clinical Trial Continuity

PHILADELPHIA – March 30, 2020 – ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a cardiac safety solution that helps biopharmaceutical researchers continue important clinical trials during current global ‘stay home’ mandates. The solution enables clinician-administered ECG readings ─ using ERT’s provisioned, FDA-cleared devices or other investigative site–owned equipment ─ to evaluate the safety of new vaccines and medical treatments from patients’ homes.
More info >>

White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement